{"ATC Code":"N05CD09","Abbreviation":"","Aliases":["Lendormin","Lendorm","Mederantil","Sintonal","WE 941","Brotizolamum","Nimbisan","WE-941","2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine","WE-941-BS"],"Biological Half-Life":"4.4 hours.","CAS":"57801-81-7","ChEBI":"CHEBI:31308","ChEMBL":"CHEMBL32479","ChemicalClasses":["thienotriazolodiazepine"],"Chirality":"achiral","Classes":null,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Brotizolam is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.","DrugClasses":[],"EINECS":"260-964-5","EliminationHalfLife":"4.4 hours (range, 2.6 – 6.9 h)","Erowid Experience Reports":[{"Author":"Ragey","Id":"96597","Title":"Not Really Sure"}],"European Community (EC) Number":"260-964-5","HeavyAtomCount":22,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"4-bromo-7-(2-chlorophenyl)-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene","Impurities":["2-bromo-4-(2-chlorophenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"],"InChI":"InChI=1S/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3","InChIKey":"UMSGKTJDUHERQW-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)","Melting Point":"211-213","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e10\u003c/sub\u003eBrClN\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"393.7 g/mol","PrevSalts":[],"PubChemId":2451,"Record Description":["Brotizolam is an organic molecular entity.","Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects. Brotizolam has similar effects to short-acting benzodiazepines such as triazolam. Brotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours).  Brotizolam is not approved for sale in the UK, United States or Canada but is sold in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.","Brotizolam is a triazolo-benzodiazepine derivative with sedative, hypnotic, anxiolytic and anticonvulsant activities. Brotizolam binds to the benzodiazepine binding site on the gamma aminobutyric acid (GABA)-A receptor in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS.","BROTIZOLAM is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.","Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to short-acting benzodiazepines such as triazolam. It is used in the short term treatment of severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). Brotizolam is not approved for sale in the UK, United States or Canada. It is approved for sale in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan.","Brotizolam is an organic molecular entity."],"RefCount":4,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Brotizolam","Name":"Brotizolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q850074","Name":"Brotizolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB09017","Name":"Brotizolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2451","Name":"Brotizolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL32479","Name":"Brotizolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31308","Name":"Brotizolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=57801-81-7","Name":"Brotizolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D01744","Name":"Brotizolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/5XZM1R3DKF","Name":"Brotizolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0022692","Name":"Brotizolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2451, Brotizolam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2451\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2451\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Brotizolam. UNII: 5XZM1R3DKF. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5XZM1R3DKF\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/5XZM1R3DKF\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 26, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e"],"SMILES":"CC1=NN=C2N1C3=C(C=C(S3)Br)C(=NC2)C4=CC=CC=C4Cl","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"United States","ref":[],"schedule":"Unscheduled substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Nations","ref":[],"schedule":"Schedule IV substance"}],"StoreUNII":["5XZM1R3DKF"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.213mm" version="1.2" viewBox="0 0 82.726 104.213" width="82.726mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="83.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="42.248" x2="55.298" y1="1.068" y2="8.939"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="66.108" x2="55.298" y1="4.374" y2="8.939"/>
                        
                <line x1="67.057" x2="57.879" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="66.108" x2="60.703" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="67.057" x2="62.468" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="72.196" x2="76.458" y1="6.31" y2="11.232"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="71.436" x2="77.112" y1="27.578" y2="18.181"/>
                        
                <line x1="70.265" x2="75.024" y1="24.801" y2="16.92"/>
                      
                <line class="hi" stroke="#3050F8" x1="77.112" x2="74.274" y1="18.181" y2="22.8795"/>
                <line class="hi" stroke="#3050F8" x1="75.024" x2="72.6445" y1="16.92" y2="20.860500000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="71.436" x2="59.907" y1="27.578" y2="24.893"/>
                  
            <line class="bond" id="mol1bnd6" x1="55.298" x2="56.272" y1="8.939" y2="20.279"/>
                  
            <line class="bond" id="mol1bnd7" x1="53.57" x2="44.715" y1="26.559" y2="33.674"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="44.715" x2="44.715" y1="48.914" y2="33.674"/>
                        
                <line x1="42.277" x2="42.277" y1="47.137" y2="35.451"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="44.715" x2="30.187" y1="48.914" y2="53.587"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="21.246" x2="30.187" y1="41.294" y2="53.587"/>
                        
                <line x1="24.261" x2="31.12" y1="41.294" y2="50.725"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="21.246" x2="27.818" y1="41.294" y2="32.257"/>
                  
            <line class="bond" id="mol1bnd12" x1="44.715" x2="33.055" y1="33.674" y2="29.923"/>
                  
            <line class="bond" id="mol1bnd13" x1="21.246" x2="7.81" y1="41.294" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd14" x1="44.715" x2="56.603" y1="48.914" y2="58.464"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="56.603" x2="68.132" y1="58.464" y2="55.779"/>
                        
                <line x1="57.205" x2="67.579" y1="55.82" y2="53.404"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.132" x2="62.36750000000001" y1="55.779" y2="57.1215"/>
                <line class="hi" stroke="#3050F8" x1="67.579" x2="62.391999999999996" y1="53.404" y2="54.612"/>
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="73.223" x2="78.04" y1="51.298" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd17" x1="71.436" x2="78.04" y1="27.578" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd18" x1="56.603" x2="53.217" y1="58.464" y2="73.323"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="53.217" x2="38.61" y1="73.323" y2="77.83"/>
                        
                <line x1="52.592" x2="40.689" y1="76.068" y2="79.741"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="38.61" x2="35.36" y1="77.83" y2="92.72"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="35.36" x2="46.497" y1="92.72" y2="103.158"/>
                        
                <line x1="38.038" x2="47.124" y1="91.887" y2="100.404"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="46.497" x2="61.125" y1="103.158" y2="98.552"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="61.125" x2="64.375" y1="98.552" y2="83.662"/>
                        
                <line x1="59.045" x2="61.696" y1="96.651" y2="84.504"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="53.217" x2="64.375" y1="73.323" y2="83.662"/>
                  
            <line class="bond" id="mol1bnd25" x1="64.375" x2="75.728" y1="83.662" y2="80.097"/>
                  
            <path class="atom" d="M71.279 5.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M81.256 16.982h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M58.543 26.573h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M31.732 30.137q-.0 .649 -.477 1.018q-.47 .363 -1.268 .363q-.416 .0 -.768 -.065q-.345 -.06 -.577 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.548 .0 .828 -.214q.279 -.214 .279 -.577q.0 -.238 -.107 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.697 -.297q-.625 -.227 -.946 -.554q-.316 -.333 -.316 -.899q.0 -.393 .197 -.667q.202 -.279 .553 -.428q.358 -.155 .816 -.155q.405 -.0 .738 .077q.34 .072 .613 .197l-.196 .53q-.25 -.114 -.548 -.185q-.297 -.077 -.625 -.077q-.458 -.0 -.69 .196q-.233 .197 -.233 .518q.0 .244 .102 .411q.107 .166 .339 .297q.232 .125 .631 .28q.429 .155 .726 .34q.298 .178 .453 .434q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M1.959 38.267q.917 -.0 1.387 .273q.47 .268 .47 .941q.0 .435 -.244 .72q-.238 .286 -.69 .363v.036q.309 .048 .559 .179q.25 .131 .393 .375q.149 .238 .149 .619q.0 .667 -.458 1.03q-.459 .363 -1.245 .363h-1.72v-4.899h1.399zM2.078 40.356q.631 .0 .863 -.202q.238 -.203 .238 -.602q.0 -.404 -.285 -.577q-.286 -.179 -.911 -.179h-.81v1.56h.905zM1.173 40.868v1.774h.988q.655 .0 .905 -.25q.256 -.256 .256 -.667q.0 -.381 -.268 -.619q-.262 -.238 -.94 -.238h-.941zM6.649 39.421q.101 .0 .22 .012q.125 .006 .208 .03l-.071 .554q-.089 -.018 -.196 -.03q-.108 -.018 -.203 -.018q-.28 .0 -.53 .155q-.244 .155 -.393 .434q-.148 .274 -.148 .649v1.959h-.602v-3.673h.494l.066 .667h.03q.178 -.298 .458 -.518q.28 -.221 .667 -.221z" fill="#A62929" id="mol1atm12" stroke="none"/>
                  
            <path class="atom" d="M73.377 57.459h-.72l-2.62 -4.066h-.029q.011 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M79.409 77.12q-.785 -.0 -1.238 .53q-.452 .524 -.452 1.446q-.0 .911 .416 1.447q.423 .53 1.268 .53q.322 -.0 .608 -.054q.291 -.059 .565 -.143v.536q-.274 .101 -.565 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q-.0 -.744 .268 -1.309q.274 -.566 .803 -.881q.53 -.322 1.28 -.322q.78 .0 1.352 .286l-.244 .524q-.227 -.101 -.506 -.185q-.274 -.083 -.608 -.083zM82.166 81.543h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm22" stroke="none"/>
                
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="72.196" x2="74.327" y1="6.31" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="76.458" x2="74.327" y1="11.232" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="59.907" x2="65.67150000000001" y1="24.893" y2="26.235500000000002"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="56.272" x2="55.785" y1="20.279" y2="14.609"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="53.57" x2="49.1425" y1="26.559" y2="30.116500000000002"/>
            <line class="hi" id="mol1bnd11" stroke="#C6C62C" x1="27.818" x2="24.532" y1="32.257" y2="36.775499999999994"/>
            <line class="hi" id="mol1bnd12" stroke="#C6C62C" x1="33.055" x2="38.885000000000005" y1="29.923" y2="31.798499999999997"/>
            <line class="hi" id="mol1bnd13" stroke="#A62929" x1="7.809999999999999" x2="14.527999999999999" y1="41.294" y2="41.294"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="73.223" x2="75.6315" y1="51.298" y2="46.296"/>
            <line class="hi" id="mol1bnd25" stroke="#1FF01F" x1="75.728" x2="70.0515" y1="80.097" y2="81.87950000000001"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Brotizolam","UNII":"5XZM1R3DKF","Wikidata":"Q850074","Wikipedia":"Brotizolam","XLogP":2.8}